LEPU BIO-B: The results of the registrational clinical study of MRG003 will be presented in LBA format at the 2025 ASCO Annual Meeting

Zhitong
2025.06.01 10:50
portai
I'm PortAI, I can summarize articles.

LEPU BIO-B announced that the key registration clinical study results of its candidate drug MRG003 will be presented as a major research abstract at the 2025 ASCO Annual Meeting, along with an oral presentation. MRG003 is an innovative antibody-drug conjugate targeting recurrent or metastatic nasopharyngeal carcinoma

According to the news from Zhitong Finance APP, LEPU BIO-B (02157) announced that the key registration clinical study results of its self-developed candidate drug MRG003 (an epidermal growth factor receptor-targeted innovative antibody-drug conjugate ("ADC") candidate drug for the treatment of recurrent or metastatic nasopharyngeal carcinoma ("R/M NPC")) will be published in the form of a "Late-Breaking Abstract (LBA)" at the 2025 American Society of Clinical Oncology ("ASCO") annual meeting, and a verbal report will be presented at the meeting

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.